Amgen Change in Accounts Payable 2010-2025 | AMGN

Amgen change in accounts payable for the twelve months ending June 30, 2025 was $2.439B, a 3287.5% increase year-over-year.

  • Amgen annual change in accounts payable for 2024 was $0.312B, a 177.61% decline from 2023.
  • Amgen annual change in accounts payable for 2023 was $-0.402B, a 361.04% decline from 2022.
  • Amgen annual change in accounts payable for 2022 was $0.154B, a 323.19% decline from 2021.

Amgen Change in Accounts Payable 2010-2025 | AMGN

  • Amgen annual change in accounts payable for 2024 was $0.312B, a 177.61% decline from 2023.
  • Amgen annual change in accounts payable for 2023 was $-0.402B, a 361.04% decline from 2022.
  • Amgen annual change in accounts payable for 2022 was $0.154B, a 323.19% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$233.7B
Gilead Sciences (GILD)$148.9B
Vertex Pharmaceuticals (VRTX)$99.4B
Bristol Myers Squibb (BMY)$94.7B
CSL (CSLLY)$83.8B
GSK (GSK)$77.9B
Regeneron Pharmaceuticals (REGN)$59B
Alnylam Pharmaceuticals (ALNY)$56.4B
Argenex SE (ARGX)$39B
BioNTech SE (BNTX)$26.7B
Insmed (INSM)$25.8B
Royalty Pharma (RPRX)$20.2B
Biogen (BIIB)$18.9B
Incyte (INCY)$15.9B
Illumina (ILMN)$15B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$14B
Ascendis Pharma (ASND)$12B
BioMarin Pharmaceutical (BMRN)$10.9B
QIAGEN (QGEN)$10.9B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Exelixis (EXEL)$10.2B
Moderna (MRNA)$10B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.3B
Exact Sciences (EXAS)$7.9B
Halozyme Therapeutics (HALO)$7.9B
Roivant Sciences (ROIV)$7.9B
Jazz Pharmaceuticals (JAZZ)$6.9B